BRAF-V600 Mutations Have No Prognostic Impact in Stage IV Melanoma Patients Treated with Monochemotherapy

Meckbach, Diana; Keim, Ulrike; Richter, Sabina; Leiter, Ulrike; Eigentler, Thomas K.; Bauer, Jürgen; Pflugfelder, Annette; Büttner, Petra; Garbe, Claus; Weide, Benjamin
February 2014
PLoS ONE;Feb2014, Vol. 9 Issue 2, p1
Academic Journal
Background: The impact of BRAF tumor mutations on the natural course of disease of melanoma patients is controversial. Patients and Methods: We analyzed the mutational status and overall survival of 215 patients receiving treatment with dacarbazine or temozolomide. All patients who started first-line treatment at our institution between 2000 and 2010 were included to prevent selection and bias due to thereafter arising therapeutic options. Results: No patient received BRAF- or MEK-inhibitors during follow-up. Survival was associated with the pattern of visceral involvement, the presence of brain metastases and the serum lactate dehydrogenase level (all p<0.001). The BRAF-V600 mutational status was not associated with survival and no differences in overall survival were detected according to age, gender or to the cytotoxic agent used for therapy. In Cox regression analysis the presence of brain metastases (hazard ratio 2.3; p<0.001) and an elevated serum LDH (hazard ratio 2.5; p<0.001) were the only factors, which independently predicted survival. Conclusions: No differences in prognosis were observed according to the BRAF mutational status in patients with distant metastasis treated with monochemotherapy.


Related Articles

  • A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma. Hersh, E. M.; Del Vecchio, M.; Brown, M. P.; Kefford, R.; Loquai, C.; Testori, A.; Bhatia, S.; Gutzmer, R.; Conry, R.; Haydon, A.; Robert, C.; Ernst, S.; Homsi, J.; Grob, J. J.; Kendra, K.; Agarwala, S. S.; Li, M.; Clawson, A.; Brachmann, C.; Karnoub, M. // Annals of Oncology;Nov2015, Vol. 26 Issue 11, p2267 

    Background: The efficacy and safety of nab-paclitaxel versus dacarbazine in patients with metastatic melanoma was evaluated in a phase III randomized, controlled trial. Patients and methods: Chemotherapy-naïve patients with stage IV melanoma received nab-paclitaxel 150 mg/m² on days 1, 8,...

  • RAS/RAF/MEK/ERK and PI3K/PTEN/AKT Signaling in Malignant Melanoma Progression and Therapy. Ichiro Yajima; Mayuko Y. Kumasaka; Nguyen Dinh Thang; Yuji Goto; Kozue Takeda; Osamu Yamanoshito; Machiko Iida; Nobutaka Ohgami; Haruka Tamura; Yoshiyuki Kawamoto; Masashi Kato // Dermatology Research & Practice;2012, Vol. 2012, p1 

    Cutaneous malignant melanoma is one of the most serious skin cancers and is highly invasive and markedly resistant to conventional therapy. Melanomagenesis is initially triggered by environmental agents including ultraviolet (UV), which induces genetic/epigenetic alterations in the chromosomes...

  • Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab. Meyer, Christiane; Cagnon, Laurène; Costa-Nunes, Carla; Baumgaertner, Petra; Montandon, Nicole; Leyvraz, Loredana; Michielin, Olivier; Romano, Emanuela; Speiser, Daniel // Cancer Immunology, Immunotherapy;Mar2014, Vol. 63 Issue 3, p247 

    Metastatic melanoma has a poor prognosis with high resistance to chemotherapy and radiation. Recently, the anti-CTLA-4 antibody ipilimumab has demonstrated clinical efficacy, being the first agent to significantly prolong the overall survival of inoperable stage III/IV melanoma patients. A major...

  • Prognostic survival model for people diagnosed with invasive cutaneous melanoma. Baade, Peter D.; Royston, Patrick; Youl, Philipa H.; Weinstock, Martin A.; Geller, Alan; Aitken, Joanne F. // BMC Cancer;2015, Vol. 15 Issue 1, p1 

    Background: The ability of medical practitioners to communicate risk estimates effectively to patients diagnosed with melanoma relies on accurate information about prognostic factors and their impact on survival. This study reports the development of one of the few melanoma prognostic models,...

  • Is chemotherapy still an option in the treatment of melanoma? Carlino, M. S.; Long, G. V. // Annals of Oncology;Nov2015, Vol. 26 Issue 11, p2203 

    No abstract available.

  • Long-term outcome of esophagectomy for primary malignant melanoma of the esophagus: a single-institute retrospective analysis. Harada, K.; Mine, S.; Yamada, K.; Shigaki, H.; Oya, S.; Baba, H.; Watanabe, M. // Diseases of the Esophagus;May2016, Vol. 29 Issue 4, p314 

    Primary malignant melanoma of the esophagus ( PMME) is a highly malignant tumor with a poor prognosis. Because PMME is an extremely rare disease, therapeutic strategies against the tumor have yet to be established, and the efficacy of esophagectomy remains unclear. The objective of this study...

  • Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC study. Schadendorf, D.; Amonkar, M. M.; Milhem, M.; Grotzinger, K.; Demidov, L. V.; Rutkowski, P.; Garbe, C.; Dummer, R.; Hassel, J. C.; Wolter, P.; Mohr, P.; Trefzer, U.; Lefeuvre-Plesse, C.; Rutten, A.; Steven, N.; Ullenhag, G.; Sherman, L.; Wu, F. S.; Patel, K.; Casey, M. // Annals of Oncology;Mar2014, Vol. 25 Issue 3, p700 

    We report the first quality-of-life assessment of a MEK inhibitor in metastatic melanoma from a phase III study. Trametinib prolonged progression-free survival and improved overall survival versus chemotherapy in patients with BRAF V600 mutation-positive melanoma. Less functional impairment,...

  • From chemotherapy to targeted treatment. Dummer, R.; Rozati, S.; Eggmann, N.; Rinderknecht, J.; Goldinger, S. M. // Annals of Oncology;Sep2012 Supplement 10, Vol. 23 Issue suppl_10, px101 

    Today, melanoma is considered as a spectrum of melanocytic malignancies that can be characterized by clinical and molecular features, including targetable mutations in several kinases. The successful development of therapies, targeting mutated BRaF (v-raf murine sarcoma viral oncogene homolog...

  • Urgent treatment of patients with metastatic melanoma using braf inhibitors in the absence of braf mutation status. Nathan, P.; Sharma, A.; Lorigan, P. // Annals of Oncology;Jun2013, Vol. 24 Issue 6, p1712 

    No abstract available.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics